Authors : Fei D; Department of Anesthesiology, Luzhou People's Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, PR China.; Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, PR China.

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/genetics ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/pathology ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/metabolism

Source: Molecular cancer [Mol Cancer] 2024 Aug 06; Vol. 23 (1), pp. 159. Date of Electronic Publication: 2024 Aug 06.Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells.

Authors : Zeng T; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.; Wang D

Subjects: Cell Proliferation*; Carcinoma, Hepatocellular/Carcinoma, Hepatocellular/Carcinoma, Hepatocellular/*pathology ; Early Growth Response Protein 2/Early Growth Response Protein 2/Early Growth Response Protein 2/*metabolism

Source: PloS one [PLoS One] 2017 May 19; Vol. 12 (5), pp. e0177843. Date of Electronic Publication: 2017 May 19 (Print Publication: 2017).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Effects of Macrothele raven venom on intrarenal invasion and metastasis of H 22 liver cancer cells in mice.

Authors : Hou Y; Department of Urological Surgery, Second Xiangya Hospital, Central South University, Changsha 410012, PR China.; Zhao X

Subjects: Carcinoma, Hepatocellular/Carcinoma, Hepatocellular/Carcinoma, Hepatocellular/*drug therapy ; Cell Proliferation/Cell Proliferation/Cell Proliferation/*drug effects ; Liver Neoplasms/Liver Neoplasms/Liver Neoplasms/*drug therapy

Source: Journal of cancer research and therapeutics [J Cancer Res Ther] 2017; Vol. 13 (4), pp. 725-729.Publisher: Medknow Publications Country of Publication: India NLM ID: 101249598 Publication Model: Print Cited Medium: Internet ISSN: 1998-4138

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

196MO Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701)

Authors : Cheng, Y.; Yang, R.; Chen, J.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102769 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

29P Real-world safety of osimertinib in Chinese patients with non-small cell lung cancer (NSCLC)

Authors : Han, B.; He, J.; Yao, W.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102608 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

20P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients post osimertinib first line treatment failure: An interim analysis of GPS study

Authors : Shi, Y-K.; Lv, D.; Feng, W.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102599 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

61P First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study

Authors : Zhou, C.; Chen, G.; Huang, Y.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102640 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial

Authors : Zhou, C.; Ren, S.; Chen, J.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102641 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

68P Phase II results of ivonescimab (ivo) a novel PD-1/VEGF bispecific in combination with chemotherapy for first-line treatment of patients (pts) with advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC)

Authors : Zhang, L.; Fang, W.F.; Zhao, Y.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102647 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Vitronectin [correction of Vitronetcin] promotes cell growth and inhibits apoptotic stimuli in a human hepatoma cell line via the activation of caspases.

Authors : Zhu W; a Department of Toxicology, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.; Liu Y

Subjects: Cell Proliferation*; Apoptosis/Apoptosis/Apoptosis/*drug effects ; Carcinoma, Hepatocellular/Carcinoma, Hepatocellular/Carcinoma, Hepatocellular/*metabolism

Source: Canadian journal of physiology and pharmacology [Can J Physiol Pharmacol] 2014 May; Vol. 92 (5), pp. 363-8. Date of Electronic Publication: 2014 Mar Publisher: Canadian Science Publishing Country of Publication: Canada NLM ID: 0372712 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway.

LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells.

Effects of Macrothele raven venom on intrarenal invasion and metastasis of H 22 liver cancer cells in mice.

196MO Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701)

29P Real-world safety of osimertinib in Chinese patients with non-small cell lung cancer (NSCLC)

20P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients post osimertinib first line treatment failure: An interim analysis of GPS study

61P First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study

62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial

68P Phase II results of ivonescimab (ivo) a novel PD-1/VEGF bispecific in combination with chemotherapy for first-line treatment of patients (pts) with advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC)

Vitronectin [correction of Vitronetcin] promotes cell growth and inhibits apoptotic stimuli in a human hepatoma cell line via the activation of caspases.

اتصل بنا

اتبع